Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

Clinical evidences have demonstrated limited efficacy of HER2-targeted therapies in patients with gastric cancer (GC). Here the authors show that survival benefit to anti-HER2 antibody Trastuzumab is reduced in GC patients with high levels of the caveolin-1 and that, in preclinical cancer models, an...

Full description

Bibliographic Details
Main Authors: Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, Melissa Lumish, Kathryn M. Tully, Sandeep Surendra Panikar, Mike Cornejo, Audrey Mauguen, Ashwin Ragupathi, Nai C. Keltee, Marissa Mattar, Yelena Y. Janjigian, Jason S. Lewis
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-30142-9

Internet

https://doi.org/10.1038/s41467-022-30142-9

Similar Items